Study on Thrombosis Therapy in German Cancer Patients

Completed

• Conditions: Cancer; Deep Vein Thrombosis; Pulmonary Embolism
• Interventions: Other: no intervention is being made

• Registration Number: NCT01559883
• Lead Sponsor: LEO Pharma

Brief Summary

The study aims to document the flow of German patients with cancer and acute deep vein thrombosis from first visit to diagnosis and treatment, the applied diagnostic procedures, and therapy modalities.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-02
• Study First Submitted: 2012-03-01
• Study First Submitted QC: 2012-03-19
• Study First Posted: 2012-03-21
• Status Verified: 2013-11
• Primary Completion: 2013-12
• Study Completion: 2013-12
• Last Update Submitted: 2014-08-14
• Last Update Posted: 2014-08-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 76

Inclusion Criteria

• patient with cancer and acute deep vein thrombosis and/or pulmonary embolism

Exclusion Criteria

• life expectancy less that 6 months
• age less that 18 years

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
all eligible patients	no intervention is being made	there is only 1 Cohort in which all patients participating in this NIS are included

Primary Outcome Measures

Name	Time	Method
treatment time on low molecular weight heparin	1 year

Secondary Outcome Measures

Name	Time	Method
patient pathways	1 year	data collection on patient pathway: who is the referring physician, physician who diagnoses deep vein thrombosis (DVT)
risk factors for DVT	1 year

Trial Locations

Locations (1)

Prof. Dr. Axel Matzdorff; 🇩🇪 Saarbrücken, Saarland, Germany